SIGN UP
LOG IN
MARKET
PFE
PFE
Pfizer
NYSE
29.31
+0.03
+0.09%
Opening 11:35 12/05 EST
OPEN
29.18
PREV CLOSE
29.28
HIGH
29.60
LOW
29.14
VOLUME
15.12M
TURNOVER
0
52 WEEK HIGH
54.93
52 WEEK LOW
28.30
MARKET CAP
165.48B
P/E (TTM)
16.08
1D
5D
1M
3M
1Y
5Y
SPYG, TMO, PFE, DHR: ETF Inflow Alert
NASDAQ · 2h ago
Goldman Sachs: Top 30 mutual fund underweight holdings, including Apple and Tesla
Goldman sachs: top 30 mutual fund underweight holdings, including apple and tesla. Goldman sachs analyzed $5 trillion of equity positions at the start of 4q 2023. The investment bank listed the stocks it was most underweight in its hedge fund trend monitor and mutual fundamentals reports.
Seeking Alpha · 3h ago
Vaxcyte's pneumococcal shot shows safety profile comparable to Pfizer's Prevnar 20
Healthcare vaxcyte's pneumococcal shot shows safety profile comparable to pfizer's prevnar 20. Vax-24 has shown a safety and tolerability profile similar to the current standard-of-care. Merck and mrk have also shown superior immunogenicity in their vaccines.
Seeking Alpha · 6h ago
Is Weakness In Pfizer Inc. (NYSE:PFE) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Pfizer's return on equity (roe) is a measure of how well a company can turn profits into profits. Pfizer's roe of 11% is above the average for its industry. The company's net income growth over the past five years is higher than the industry average. The firm's earnings growth is expected to be similar to its earnings growth rate. Pfizer has a good roe and a low payout ratio for a company of its size.
Simply Wall St · 6h ago
Analysts Conflicted on These Healthcare Names: Natera (NTRA), ImmunoGen (IMGN) and Pfizer (PFE)
TipRanks · 11h ago
Johnson & Johnson Vs. Pfizer: Better Pharma Stock?
Johnson & johnson demonstrates better r&d efficiency and has a larger patent portfolio compared to pfizer. Jnj's product pipeline in the pharmaceutical segment has more late-stage developments. Pfizer has a stronger financial position for future m&a activities, but jnj acquisitions are more diversified.
Seeking Alpha · 12h ago
Tracking Baker Brothers Portfolio - Q3 2023 Update
Baker brothers' 13f portfolio value increased marginally from $17.28b to $ 17.35b in q3 2023. The largest five stakes in the portfolio are seagen, beigene, incyte, acadia pharma, and biomarin pharma. Stake increases were seen in rhythm pharma, abcellera biologics, and kymera therapeutics.
Seeking Alpha · 15h ago
Blackstone explores sale of Anthos Therapeutics -sources
NASDAQ · 18h ago
About PFE
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
Webull offers Pfizer Inc. stock information, including NYSE: PFE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PFE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading PFE stock methods without spending real money on the virtual paper trading platform.